Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific reports satisfaction with Q2 2011 performance

Boston Scientific reports satisfaction with Q2 2011 performance

29th July 2011

Boston Scientific has reported its financial results for the second quarter of 2011, with figures gravitating towards the high end of its guidance.

The company's sales total came to just under $2 billion (1.2 billion pounds), a 66 percent increase over the corresponding period of 2010, which was attributed to strong execution of its Power business strategy.

Earnings per share exceeded the company's estimate range, which has led to an upward revision of its targets for the full year, while a new restructuring programme has been announced that is set to deliver significant savings.

Other highlights of the quarter include the launch of the Energen and Punctua devices in Europe, as well as the introduction of the Ion drug-eluting stent in the US.

Ray Elliott, president and chief executive officer of Boston Scientific, said: "We remain confident that Boston Scientific is powered for long-term, sustainable growth."

Earlier this month, the company completed enrolment for a new clinical study of its Adapt Monorail carotid stent system for carotid artery disease patients.ADNFCR-8000103-ID-800638904-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.